Activity Chair:
Christopher P. Cannon, MD
Professor of Medicine, Harvard Medical School
Executive Director of Cardiometabolic Trials
Harvard Clinical Research Institute
Senior Investigator, TIMI Study Group
Cardiovascular Division
Brigham and Women's Hospital
Boston, MA
Planning Committee and Faculty:
Marc P. Bonaca, MD, MPH
Investigator TIMI Study Group
Vascular Medicine Section
Cardiovascular Division
Brigham and Women’s Hospital Heart and Vascular Center
Boston, MA
Kenneth W. Mahaffey, MD
Professor of Medicine, Stanford University School of Medicine
Vice Chair of Clinical Research, Department of Medicine
Director, Stanford Center for Clinical Research (SCCR)
Stanford, CA
Philippe Gabriel Steg, MD
Université Paris Diderot
INSERM U-1148
Hôpital Bichat, AP-HP
Paris, France
Reviewers:
David Davidson, MD
Ronald Codario, MD, FACP, FNLA, RPVI, CHCP (Recertification review on 1/11/2018)
Disclosures:
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears on this page and the next page.
Activity Chair and Faculty members repors the following relationship(s) which are accurate at the time of original content release (February 24, 2016):
Christopher P. Cannon, MD
Served as an advisor or consultant for: Boehringer Ingelheim, Bristol-Myers Squibb, CSL Behring, Essentialis, Pfizer, Merck, GlaxoSmithKline, Lipimedix, Regeneron, Sanofi, Takeda
Received grants for clinical research from: Accumetrics, Arisaph, Janssen, AstraZeneca, Merck, Boehringer Ingelheim, GlaxoSmithKline, Takeda
Marc P. Bonaca, MD, MPH
Served as an advisor or consultant for: AstraZeneca, Merck, Bayer, Roche
Other: PEGASUS-TIMI 54: funded by a research grant to Brigham and Women’s Hospital from AstraZeneca
Kenneth W. Mahaffey, MD
Served as an advisor or consultant for: AstraZeneca, Bristol-Myers Squibb, Bayer, Boehringer Ingelheim, Cubist, Eli Lilly, Epson, Forest, Springer, Medtronic, Merck, GlaxoSmithKline, Johnson & Johnson, Mt. Sinai, WebMD, Myokardia, Omthera, Portola, Purdue, TMC
Received grants for clinical research from: Amgen, Daiichi, Johnson & Johnson, Medtronic, St. Jude, Tenax
Owns stock, stock options, or bonds from: BioPrint Fitness
Philippe Gabriel Steg, MD
Served as an advisor or consultant for: Amarin, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, CSL-Behring, Daiichi Sankyo/Lilly, Janssen, GlaxoSmithKline, Merck-Sharpe Dohme, Pfizer, Novartis, Regeneron, Sanofi, The Medicine Company, Servier
Received grants for clinical research from: Servier, Sanofi
Owns stock, stock options, or bonds from: Aterovax
Reviewers report the following relationship(s):
David Davidson, MD
No relevant financial relationships to disclose.
Ronald A. Codario, MD, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.
Vindico Medical Education staff report the following relationship(s):
No relevant financial relationships to disclose.
Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Unlabeled and Investigational Usage:
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.